 "Zydus Cadila decides to exit Japan biz")
In a filing to the Bombay Stock Exchange (BSE) this afternoon the company informed that, "The company has recently completed portfolio and strategy review of its business and has decided to exit from its business in Japan, which is through 100 per cent subsidiary company."
The firm has operations spread across the US, Europe, Japan, Brazil, South Africa and 25 other emerging markets. Zydus had acquired Nippon Universal Pharmaceuticals Ltd in 2007 to strengthen its base in the country. The company could not be reached for a comment.
Cadila Healthcare's shares fell 2.24 per cent on BSE today and closed at Rs 819 a share.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%